The continued EGFR-TKI with cytotoxic chemotherapy at progression—poison or medicine?

Ítems similars

• The different path of T790M-positive EGFR-mutant lung cancer
  per: Yoon, Shinkyo, et al.
  Publicat: (2018)
• Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
  per: Kwon, Byoung Soo, et al.
  Publicat: (2017)
• The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
  per: Fu-Tsai Chung, et al.
  Publicat: (2015-01-01)
• The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
  per: Chung, Fu-Tsai, et al.
  Publicat: (2015)
• Autophagosome-Mediated EGFR Down-Regulation Induced by the CK2 Inhibitor Enhances the Efficacy of EGFR-TKI on EGFR-Mutant Lung Cancer Cells with Resistance by T790M
  per: So, Kwang Sup, et al.
  Publicat: (2014)